{'fraction_non_alphanumeric': 0.05139186295503212, 'fraction_numerical': 0.035331905781584586, 'mean_word_length': 4.5325443786982245, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.

AIM
We reviewed the clinical use of daptomycin in daily practice.


MATERIALS & METHODS
Efficacy and safety were assessed in 175 consecutive patients given daptomycin for at least 72 h.


RESULTS
Daptomycin was given as rescue treatment in 50.9% of cases. Bloodstream infection (34.8%) and skin/soft-tissue infection (19.4%) were the most frequent. In 62.3% of patients, the dose of ≤ 6 mg/kg/day was administered. Staphylococcus spp. were isolated in 52.6% of cases (MRSA in 9.5%, CoNS in 34.3%) and Enterococcus spp. in 8.7%. Clinical success was 75% and microbiological eradication 48.6%. Two patients discontinued daptomycin due to hemolytic anemia of unlikely and possible relationship with daptomycin, respectively.


CONCLUSION
Daptomycin was effective and well tolerated in patients with severe Gram-positive infections.